RTP Mobile Logo
Visiting Professors: Prostate Cancer Edition, Issue 1, 2011
Released December 2011

Featuring Dr Matthew R Smith’s perspective on a day spent visiting patients with prostate cancer in the clinic of community oncologist Dr Stacey B Leibowitz. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    An estimated 220,000 new cases of prostate cancer are diagnosed yearly in the United States and account for approximately one third of new cancer cases among men. Published results from clinical trials lead to the emergence of new local and systemic therapeutic approaches, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To provide clinicians with therapeutic strategies to address the disparate needs of patients with prostate cancer, the Visiting Professors audio series employs an innovative case-based approach that unites the perspectives of leading prostate cancer investigators and community oncologists as they explore the intricacies of making treatment decisions. Upon completion of this CME activity, urologic oncology physicians should be able to formulate an up-to-date and more complete approach to the care of patients with prostate cancer.

    LEARNING OBJECTIVES
    • Use case-based learning, innovative communication strategies and shared clinical insight to provide comprehensive and compassionate oncology care.
    • Develop a rational evidence-based approach to the use of bone-targeted therapies for patients with early and advanced-stage prostate cancer.
    • Counsel patients with metastatic castration-resistant prostate cancer (mCRPC) about the effects of docetaxel and cabazitaxel on quality and quantity of life.
    • Recall existing and emerging research information demonstrating the efficacy and tolerability of abiraterone acetate for patients with chemotherapy-pretreated CRPC, and use this information to guide treatment.
    • Compare and contrast the efficacy, safety and tolerability of evidence-based chemotherapy and immunotherapy for patients with mCRPC.
    • Evaulate symptoms, tumor burden and pace of disease, and factor these into the integration of sipuleucel-T in the treatment algorithm for mCRPC.
    • Synthesize the emerging data and active research evaluating novel agents — including tyrosine kinase inhibitors, radiopharmaceuticals, androgen biosynthesis inhibitors and antiandrogens — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Leibowitz had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SmithConsulting Agreement: Amgen Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Sanofi.

    H
    ardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2011
    Expiration date: December 2012

Acknowledge and close

Listen to audio:
Visiting Professors: Prostate Cancer Edition, Issue 1, 2011
Released December 2011

Featuring Dr Matthew R Smith’s perspective on a day spent visiting patients with prostate cancer in the clinic of community oncologist Dr Stacey B Leibowitz. (Audio Content)

Read print: